| +0.20 / +0.24%|
Services to the Health Industry
Covance, Inc. provides drug development services to pharmaceutical, biotechnology and medical device industries. It also provides laboratory testing services to the chemical, agrochemical and food industries. The company operates its business through two segments: Early development services and Late-stage development services. The Early development services segment includes discovery support services, preclinical services and clinical pharmacology services. The company's preclinical services include toxicology services, pharmaceutical chemistry and related services. Its other services include in vivo toxicology studies, which are studies of the effects of drugs in animals, genetic toxicology studies, which include studies of the effects of drugs on chromosomes, as well as on genetically modified mice, and other specialized toxicology services. The company supports early-stage development through preclinical studies and clinical pharmacology services, including first-in-human trials. The Late-stage development services segment includes central laboratory services, clinical development services, clinical trial support services & market access services. Covance was founded in 1987 and is headquartered in Princeton, NJ.
|Joseph L. Herring||Chairman & Chief Executive Officer|
|Alison A. Cornell||Chief Financial Officer & Vice President|
|William E. Klitgaard||Chief Information Officer & Senior Vice President|
|Thomas G. Turi||Vice President-Biomarkers|
|Steven M. Michael||Chief Scientific Officer & Vice President|